Quotables
"There is practically no chance communications space satellites will be used to provide better telephone, telegraph, television, or radio service inside the United States."
T. Craven, FCC Commissioner ; 1961
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7311912 | Epithelial tissue targeting agent Targeting molecules for use in delivering biological agents to epithelial tissue are disclosed. Upon delivery, the biological agent(s) may remain within an epithelial cell or may undergo transepithelial transport via transcytosis. The targeting molecules may be used... | 12/25/2007 |
| 6833131 | Antivenom immunesera An antivenom comprising a mixture of monospecific antisera each raised against venoms of one species or sub-species is disclosed. Also disclosed is a pharmaceutical composition comprising the antivenom of the invention, and a method of treating envenomation in a mam... | 12/21/2004 |
| 6656468 | Clostridial toxin disease therapy Treating humans and animals intoxicated with a bacterial toxin by administration of antitoxin. Avian antitoxin in an aqueous solution in therapeutic amount that is orally administrable.... | 12/02/2003 |
| 6646108 | Process for isolating IgG and IgA A method for the separation of IgG and IgA from an immunoglobulin-containing starting material is described, whereby the method is characterized in that (i) IgG and optionally IgA are adsorbed to a solid inorganic carrier material, (ii) IgA is isolated fr... | 11/11/2003 |
| 6613326 | Antitoxins and methods for making antitoxins Effective antitoxins are demonstrated for prophylactic or causal immunotherapy. A method of generating antitoxin composed of highly-pure antibodies is described as an important defense against naturally-occurring plant and/or bacterial toxins.... | 09/02/2003 |
| 6346247 | Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies The prevention and treatment of autoimmune disease in humans (as well as other animals) is described through the use of ligands directed to cytokines. Antibodies and receptors to the proinflammatory cytokines IL-2, TNF, IL-12 and IFN-gamma are employed (a... | 02/12/2002 |
| 6287568 | Methods relating to immunogenic dextran-protein conjugates This invention includes the conception of T-independent conjugate-vaccines and its application in the induction of antigen specific IgA response. We demonstrated that 1) (1,6)dextran can elicit a markedly enhanced IgA response in T-cell free mice (... | 09/11/2001 |
| 5827534 | Oral dosage composition comprising zonnula occludens toxin and a therapeutic agent for intestinal delivery An oral dosage composition for intestinal delivery of a therapeutic agent comprising: (A) a therapeutic agent selected from the group consisting of a drug compound, a biologically active peptide and a vaccine; and (B) an intestinal absorption enhancing effecti... | 10/27/1998 |
| 5741489 | Passively administered antibody that enhances feed conversion efficiency A method for increasing feed conversion efficiency in mammals, such as swine, wherein the mammal is fed a diet containing an antibody produced using the enzyme urease as the antigen.... | 04/21/1998 |
| 5585098 | Oral administration of chicken yolk immunoglobulins to lower somatic cell count in the milk of lactating ruminants A method for lowering somatic cell count in the milk of a lactating ruminant is disclosed. IgY antibodies are first obtained from the egg of a hen which has been actively immunized against one or more mastitis-causing pathogenic organisms by injection wit... | 12/17/1996 |
| 5340923 | Methods for making and purifying antivenoms Antivenoms suitable for treatment of humans and animals as well as for analytical use. A method wherein individual venoms are used to immunize and the resulting antivenoms are, thereafter, purified individually prior to mixing. Immunization is performed i... | 08/23/1994 |
| 5308614 | Methods for the production of antibodies and induction of immune responses to tumor-associated gangliosides by immunization with ganglioside lactones The present invention relates to an improved method for the production of antibodies to tumor-associated gangliosides using ganglioside lactones. The resulting antibodies are useful in the detection and treatment of tumors containing gangliosides. The pre... | 05/03/1994 |
| 5258177 | IgA preparation and process of making the same A method of preparing an IgA rich preparation comprising exposing a plasma fraction to an amino acid, organic salt or inorganic salt with optional chromatographic treatment yielding a product suitable for use in medical conditions treatable with IgA.... | 11/02/1993 |
| 5202422 | Compositions containing plant-produced glycopolypeptide multimers, multimeric proteins and method of their use The present invention contemplates glycopolypeptide multimers having a polypeptide that contain an immunoglobulin amino acid residue sequence and an oligosaccharide that comprises a core pentasaccharide and N-acetylglucosamine-containing outer branches, s... | 04/13/1993 |
| 5171667 | Hybridomas producing monoclonal antibodies to mono-, di- and trifucosylated type 2 chain Hybridoma cell lines that produce monoclonal antibodies that differentially recognize glycolipids with mono-, di-, and trifucosylated type 2 chain structures are disclosed. The monoclonal antibodies can be used to detect specific types of tumor cells that... | 12/15/1992 |
| 5169627 | Oral pharmaceutical composition containing a polyethylene glycol-immunoglobulin G conjugate for reconstitution of secretory immunity and method of reconstituting secretory immunity Polyethylene glycol serum immunoglobulin conjugates exhibit substantial rstance to degradation by intestinal enzyme while retaining their immuno-activity. Thus, PEG-IgG or PEG-IgA conjugates can be used as orally administered therapeutics to treat patien... | 12/08/1992 |
| 5151266 | Use of anionic detergents with conjugates of monoclonal or polyclonal antibodies Methods are disclosed for increasing the solubility of antibodies and their radioisotope, toxin, or drug immunoconjugates and for reducing the non-specific uptake of antibody, either conjugated or unconjugated, into the RES organs such as via Fc receptor-... | 09/29/1992 |
| 5130127 | Human tumor therapy using beta (1-3) glucanlentinan and anti-tumor antibodies A therapeutic method for treating human tumors in vivo is provided wherein lentinan is administered to the patient followed by treatment with anti-tumor monoclonal antibodies.... | 07/14/1992 |
| 5091178 | Tumor therapy with biologically active anti-tumor antibodies A method for identifying and using antibodies which are directed against tumor-associated glycolipid antigens and which are capable of activating serum complement or antibody dependent cellular cytotoxicity. These antibodies find use in the therapy of tum... | 02/25/1992 |
| 5082931 | Type II bacterial Fc receptors A type II, proteinaceous, antigenic factor derived from a Group A streptococci which is a receptor for the Fc region of human Ig G3 and which exhibits a major diffuse protein band on polyacrylamide gel electrophoresis and which has a molecular weight of a... | 01/21/1992 |
| 5055559 | Anti-melanoma antibody MG-21 for diagnosis and therapy of human tumors An antibody MG-21 which is directed against a tumor-associated glycolipid antigen and which is capable of activating serum complement or antibody dependent cellular cytoxicity is described. This antibody finds use in the therapy of cancers particularly me... | 10/08/1991 |
| 5004694 | Complement-dependent cytolytic anti-Trichomonas vaginalis monoclonal antibodies Novel monoclonal antibodies specific to Trichomonas vaginalis, having complement--fixing ability and lysing Trichomonas vaginalis in the presence of complement are disclosed and may be used in therapy and diagnosis of trichomoniasis. Hybridomas producing ... | 04/02/1991 |
| 4965068 | Polyvalent hyperimmunoglobulin preparation The present invention involves a polyvalent hyperimmunoglobulin preparation having activity against gram negative and gram positive bacteria. Such a polyvalent hyperimmunoglobulin preparation is prepared from plasma, serum or whole blood from donors. Dono... | 10/23/1990 |
| 4962188 | Recombinant ricin toxin A chain conjugates Conjugates comprising recombinant ricin toxin A chain and a binding moiety which may be an antigen binding portion selected from the group consisting of Fab, Fab' and F(ab')2 fragments of monoclonal or polyclonal antibodies, hormones, lectins o... | 10/09/1990 |
| 4958009 | Anti-human ovarian cancer immunotoxins and methods of use thereof Immunotoxins comprising a cytotoxic moiety and monoclonal antibodies which bind to human ovarian cancer tissue having at least one of the following capabilities are claimed: cytotoxic ID50 of 10 nM or less against human ovarian cancer cells, re... | 09/18/1990 |
| 4956453 | Anti-human ovarian cancer immunotoxins and methods of use thereof Immunotoxins comprising a cytotoxic moiety and an antigen binding portion selected from the group consisting of Fab, Fab' and F(ab')2 fragments of a monoclonal antibody, which binds to human ovarian cancer tissue, having one of the following ca... | 09/11/1990 |
| 4938948 | Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies Hybridomas producing monoclonal antibodies suitable for imaging and diagnosis of human breast tumors and such monoclonal antibodies are claimed. The monoclonals are characterized by breast tumor binding range, breast cancer cell line range, and selectivit... | 07/03/1990 |
| 4894229 | Carrier-bound immunogenic determinants and carrier therefor An immunogenicity increasing carrier substance for immunogenic determinants is composed of particles derived from gram-negative cells substantially devoid or depleted of their natural immunogenic determinants, more particularly prepared by stripping the O... | 01/16/1990 |
| 4885358 | Monoclonal antibodies specific for synthetic glycosphingolipids having abnormal branched structure Hybridomas which produce monoclonal antibodies specific to an abnormal branched determinant of a synthetic glycolipid antigen and methods of use of the monoclonal antibodies.... | 12/05/1989 |
| 4880913 | Process for the preparation of an immunoglobulin which can be administered intravenously and is stable in liquid form The invention relates to a process for the preparation of an immunoglobulin which has no side effects, is stable on storage in liquid form and can be administered intravenously and which has a monomer content above 97%, in which euglobulins and other impu... | 11/14/1989 |
| 4876199 | Hybridomas producing monoclonal antibodies to mono-, di-, and trifucosylated type 2 chain Hybridoma cell lines that produce monoclonal antibodies that differentially recognize glycolipids with mono-, di-, and trifucosylated type 2 chain structures are disclosed. The monoclonal antibodies can be used to detect specific types of tumor cells that... | 10/24/1989 |
| 4851511 | Monoclonal antibody that specifically binds to disialosyl Lea Disialosyl Lea (IV3 NeuAcIII6 NeuAcIII4 FucLc4), a novel human cancer-associated fucoganglioside that is highly immunogenic. Also, a hybridoma cell line (ATCC No. HB 8861)secreting a monoclonal IgG3 a... | 07/25/1989 |
| 4844893 | EX vivo effector cell activation for target cell killing A method and composition for killing target cells is disclosed. The method utilizes ex vivo IL-2 activation of leucocyte effector cells and arming the activated leucocyte effectors with monoclonal antibodies whose Fc portions bind to the IL-2-activated ef... | 07/04/1989 |
| 4841024 | Purification of antibodies I(g)G3 antibody is purified by affinity chromatography and collection of released antibody at a pH of 9.0 to 9.6. The purification is effected in a column containing both an affinity matrix and a desalting matrix, with the column being equilibrated to a p... | 06/20/1989 |
| 4753894 | Monoclonal anti-human breast cancer antibodies Murine monoclonal antibodies are prepared and characterized which bind selectively to human breast cancer cells, are IgGs or IgMs, and when conjugated to ricin A chain, exhibit a TCID 50% against at least one of MCF-7, CAMA-1, SKBR-3, or BT-20 cells of le... | 06/28/1988 |
| 4734279 | Combination of immunoglobulins with therapeutic agents A compositon for treating diseases which comprises a therapeutically effective amount of an antibacterial, antiviral, or antimycotic agent, antitrypsin, antithrombin, interferon, or lysozyme, and an immunoenhancing amount of immunoglobulins IgG, IgM, and ... | 03/29/1988 |
| 4731244 | Monoclonal antibody therapy A method of seriatim administration to a patient of a plurality of ligands, each of which contains an antigen combining site of a monoclonal antibody of distinct idiotype, is disclosed. This method is useful for therapeutic as well as diagnostic purposes.... | 03/15/1988 |
| 4698420 | Antibody hybrid molecules and process for their preparation Antibodies which contain reduced sulfhydryl groups in proximity of the carboxyl terminal end of their heavy chain are coupled to another moiety which has an available sulfhydryl for forming a disulfide bond with the antibodies. IgM is a typical antibody w... | 10/06/1987 |
| 4550019 | Manufacture and use of fowl egg antibodies Immunological preparations are prepared by immunizing hens with an immunogen having a molecular or particle weight of at least 30,000, to a stage of hyper-immunization at which there occurs a plateau-like levelling-off of the antibody content of the serum... | 10/29/1985 |
| 4455296 | Hybrid cell lines producing monoclonal antibodies directed against Haemophilus influenzae Continuous hybrid cell lines for producing monoclonal antibodies directed against outer membrane antigens of Haemophilus influenzae type b have been developed. The hybrid cell lines were established by fusing differentiated lymphoid cells primed with oute... | 06/19/1984 |
